

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO)	Complet if Known			
				Applicati n Number	09/436,892		
11	NFOF	RMAT	TION DISCLOSURE	Filing Date	11/9/99	AIO	
S	STATEMENT BY APPLICANT			First Named Inventor	Medford	1 440 - 4	
				Group Art Unit	1646	2 2000 B	
(use as many sheets as necessary)			ny sheets as necessary)	Examiner Name		THE AND	
Sheet	1	of	3	Attorney Docket Number	ATH111	RADEMARKOR	

	,				PATENT DOCUMENTS			
Examiner Initials*	Cite No.		U.S. Patent Docum	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	I DAGG ONDUNE PURCO	
518	AA		4,522,811		Eppstein et al.	06-11-1985		
9/2	AB		5,155,250		Parker et al.	10-13-1992		-
0%	AC		5,262,439		Parthasarathy	11-16-1993		
XX.	AD		5,380,747		Medford et al.	01-10-1995		
<i>7</i> /2	AE		5,608,095		Parker et al.	03-04-1997		_
9K	AF		5,750,351		Medford et al.	05-12-1998		
PX	AG		5,773,209		Medford et al.	06-30-1998		
88	AH		5,773,231		Medford et al.	06-30-1998		
976	Al		5,792,787		Medford et al.	08-11-1998		
D/X	AJ		5,807,884		Medford et al.	09-15-1998		
2/3/	AK		5,811,449		Medford et al.	09-22-1998		
87	AL		5,846,959		Medford et al.	12-08-1998		
88	AM		5,877,203		Medford et al.	03-02-1999		
				FOREIGI	N PATENT DOCUMENTS			
ı			Foreign Patent Docum		YPATENI DOCUMENTS	Date of Bublication I		
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۱ ا
78.1	AN	wo	WO 95/15760		Merrell Dow Pharma.	06-15-1995		† ⊽
VZX I	AO	wo	WO 98/51662		AtheroGenics, Inc.	11-19-1998		+
88	AP	wo	WO 98/51289		AtheroGenics, Inc.	11-19-1998		+
20-	AO	_FR_	2168137		Dynachim	08-31-1973		+
1	AR.	FR	2140771		Aries	01 19 1973		十
	AS	FR	2140709		Aries	01-19-1973		+
	AT	FR	2134810		Aries	11-13-1972		†
	AU-	-FR-	2133024		Aries	11-24-1972		+
<u> </u>	AV	-FR-	2130975		Aries-	11-10-1972		1
xaminer ignature			Dnilene	B. E	Jahr 1	Date Considered	1/24/01	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Includ copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form haould be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known				
				Applicati n, Number	09/436,892	
INFORMATION DISCLOSURE				Filing Date	11/9/99 OIP	`
ST	STATEMENT BY APPLICANT			First Named Inventor	Medford	
				Group Art Unit	1646 MAR 0 2 2000 🕄	
	(use as many sheets as necessary)			Examiner Name		·
Sheet	2	of	3	Attorney Docket Number	ATH111	······································
					DRMARK	

						DEMARKS	
		·		N PATENT DOCUMENTS			
Examiner	Cite -	Foreign Patent Docu		de Name of Patentee of Applicant	Date of Publication	Pages, Columns, Lines, Where	
Initials*	No.	Number	Kind Code		of Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	
		<u> </u>	(if known)			i iguics Appeal	
ST!	ВА	WO 97/15546	stract	Shinyaku	05-01-1997		
U/8.	BB	WO 95/15760		MERRELL DOW	06-26-1995		
arx	BC	WO 95/30415		Medford et al.	11-16-1995		
00							
		 	1				
			 	-			
		· · · · · · · · · · · · · · · · · · ·					
т				<u> </u>			
						· · · · · · · · · · · · · · · · · · ·	
			 				
			ļ				
			ļ				
			<u> </u>				
		· · ·					
			<u> </u>				
			•				
xaminer		\$ 10	0	X 4 0	Date	17	
Signature		Drilere	<i>[</i>].	Dale V	Considered	1/24/01	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form hasuld be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for	Substitute for form 1449A/PTO			C mpl te if Kn wn			
				Applicati n Number	09/436,892		
IN	IFOR	MATIC	N DISCLOSURE	Filing Dat	11/9/99	70,24	
S	TATE	MENT	BY APPLICANT	First Named Inventor	Medford	MAR O 2 5	
				Group Art Unit	1646	PA 2000 55	
	(use	as many :	sheets as necessary)	Examiner Name		The state of the s	
Sheet	3	of	3	Attorney Docket Number	ATH111	DEMARK	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
XX	CA	BROWN, L., and Langer, R., Transdermal Delivery of Drugs, Annual Review of Medicine, 39:221-229 (1988),	
Q82	СВ	BROWN, M.S. and Goldstein, J. L. Sci. American (1984) 251, 58-66.	
90X	CC	CAREW et al. Proc. Natl. Acad. Sci. U.S.A. 84:7725-7729 (1987)	
00		ENDO A:	<u> </u>
7 %		GALEANO, N. F.et al., J. Biol. Chem. vo. 269, no. 1, pp. 511-519, 1994.	L
12		GOLDSTEIN, J.L. and Brown, M.S.: Ann. Rev. Biochem. (1977) 46, 897-930.	L
0/16	CG	GRUNDY S.M. New Engl. J. Med. (1988) 319: 24-32	
9X		GRUNDY S.M., Vega G.L.: Amer J. Med. (1987) 83:9-20.	
9%	CI	INNERARITY, T., et al., Proc. Natl. Acad. Sci. USA, vol. 84, pp. 6919-23, 1987.	
<i>\$</i> 57		YANG et al. Nature (1986) 323:734-738.	L
<i>Q</i> %		MILNE, R. et al., J. Biol. Chem. vol. 264, no. 33, 1988, pp. 10754-60.	
4/		MILNE, R. et al., Arteriosclerosis, vol. 3, no. 1, 1983, pp. 23-30.	L
6%	СМ	SIRTORI, C.R., Franceschini G.: Pharmac Ther. (1988) 37:167-191.	
<i>8</i>	CN	STEDRONSKY ER: Biochim. Biophys. Acta(1994) 1210:255-287.	
45/	CO	WANG X, Bucala R, Milne R. Proc. Natl. Acad. Sci (1998) 95:7643-7647.	
84	СР	WEISGRABER, K. H., et al., J. Biol. Chem., vol. 258, No. 20, October 25, 1983, pp. 12348-12354.	
102/	CQ	WILSON M.D., Rudel L.L.: J. Lipid Res. (1994) 35:943-955.	
2/8	CR	YOUNG, et al. J. Clin. Invest., Vol. 79, June 1987, 1831-1841.	
8/	CS	W. FRISHMAN, M.DZIMETBAUM, P., M.D., and H. Eder, M.D.: Clin. Pharmacol. (1990) 30:3-9.	
00			

_					
Examiner	A i Come	A	Dahel	Date	1/24/01
Signature	- Anchi	ζ''	٠	Considered	1 1 1

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form hould be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO MAY 0 8 2000 %		Complete if Known
	Application Number	09/436,892
INFORMATION DISCLOSURE	Filing Date	11/9/99
STATEMENT BY APPEILANT	First Named Inventor	Medford
· · · · · · · · · · · · · · · · · · ·	Group Art Unit	1646
(use as many sheets as necessary)	Examiner Name	
Sheet 1 of 2	Attorney Docket Number	ATH111

				U.S. P	ATENT DOCUMENTS			
Examiner	Cite		U.S. Patent Docum	ent Kind Code	Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, Whe Relevant Passages or Releva	
Initials*	No.		Number	(if known)	of Cited Document	MM-DD-YYYY	Figures Appear	
						•		_
						GEARIVE	D	_
						RECEIVE	bu .	_
						MAY 16 to		_
						TENDENTER 18	Misana	_
				<u> </u>				_
				-07510	L DATENT DOCUMENTS			_
	-	·	Farrian Detect Dogu		N PATENT DOCUMENTS	Date of Publication	Pages, Columns, Lines,	Г
Examiner Initials*	Cite No.	Office	Foreign Patent Docu Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
CH	AA	wo	94 20083		Picower Inst Med Res	09-15-1994	line 18-33; claim 27	
00								F
	_							F
								ŀ
	-							
						Date 1 Dular		_
Examine Signatur		E	milene	A.E	takel	Considered	1/24/61	_

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form hould be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

Please type a plus sign (+) inside this box	+
ricase type a pius sign (1/ mater and a m	1

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, to persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute for			MAY 0 8 2000 C	Application Number	09/436,892	
IN	1FOF	MATIO	N DECLOSURE	Filing Date	11/9/99	
S	TAT	EMENT	BY ARPLICANT	First Named Inventor	Medford	
ū			TAUEMA	Group Art Unit	1646	
	luce	2 VIRIN 28 (sheets as necessary)	Examiner Name		
Sheet	2	of of	2	Attorney Docket Number	ATH111	
Silvet	<u> </u>					

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
029/	ВА	KNOTT, TJ, et al. Complete protein sequence and identification of structural domains of human apolopoprotein B," <i>Nature</i> , 232, 734-738, 1986.	
872	ВВ	YANG, C.Y. et al. Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100 <i>Nature</i> 323, 738-742 (1986).	
1) h			
			-
			\vdash
			\vdash
			-
	 		
 	 		
 	 		_
	 		
 			<u> </u>
 	-		<u> </u>
	+-		↓_
 	 		├-
	1		╀
			+-
			†-
	<u> </u>		\vdash
			T
	<u> </u>		
Examin	_	Garline B. Dabel Date 1/24/61	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form haould be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.